Notably, GPR65 expression also influences immunotherapy outcomes: in a mouse model of B-cell acute lymphoblastic leukemia, low GPR65 expression conferred resistance to CD19 + CAR T therapy, partly by remodeling tumor–macrophage interactions. This evidence concerns the gene GPR65 and neoplasm.